Daria Ripani1, Carmelo Caldarella2, Tommaso Za3, Daniele Antonio Pizzuto1, Elena Rossi4, Valerio De Stefano4, Alessandro Giordano1. 1. Istituto di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy. 2. U.O.C. Medicina Nucleare e Centro PET-TC, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy. carmelo.caldarella@policlinicogemelli.it. 3. Istituto di Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 4. Istituto di Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy.
Abstract
PURPOSE: The purpose of this study was to determine retrospectively, through a single-center evaluation, whether FDG PET-CT normalized semi-quantitative parameters may predict response to induction chemotherapy (iChT) and hematopoietic stem cell transplantation (HSCT), as well as disease progression and progression-free survival in multiple myeloma (MM) patients, thus becoming a tool of personalized medicine. METHODS: Patients undergoing iChT and HSCT with baseline and post-treatment FDG PET-CTs from January 2008 to July 2015 were included. The following baseline and post-treatment parameters were obtained: SUVmax, SUVmean, SUVpeak, MTVsum, TLGsum, rPET (lesion SUVmax/liver SUVmax) and qPET (lesion SUVpeak/liver SUVmean). Baseline-to-post-treatment changes (Δ) were also calculated. Metabolic and clinical laboratory progression or response at follow-up were noted; time-to-metabolic-progression (TMP) was defined as the interval from post-treatment scan to eventual progression at follow-up FDG PET-CTs. Possible association between each functional parameter and metabolic/clinical-laboratory progression or response was determined. Kaplan-Meier curves allowed to depict the TMP trend according to FDG PET-CT parameters. RESULTS: Twenty-eight patients were included. Significantly higher ΔrPET and ΔqPET values were observed in ten patients with "metabolic response", with respect to 18 patients having "metabolic progression" (median 0.62 [IQR 0.32 - 1.34] vs median 0.00 [IQR -0.25 - 0.49] for ΔrPET; P = 0.045; median 0.51 [IQR 0.32 - 1.13] vs median 0.00 [IQR -0.31 - 0.67] for ΔqPET; P = 0.035). Neither normalized nor non normalized parameters differed significantly between the 20 patients with "clinical-laboratory response" and the eight patients with "clinical-laboratory progression". ΔrPET value lower than 0.38 and ΔqPET value lower than 0.27 predicted a significantly shorter TMP (P = 0.003 and P = 0.005, respectively). CONCLUSIONS: Normalized semi-quantitative parameters are effective in predicting persistent response to treatment and shorter TMP in patients with MM undergoing iChT and HSCT.
PURPOSE: The purpose of this study was to determine retrospectively, through a single-center evaluation, whether FDG PET-CT normalized semi-quantitative parameters may predict response to induction chemotherapy (iChT) and hematopoietic stem cell transplantation (HSCT), as well as disease progression and progression-free survival in multiple myeloma (MM) patients, thus becoming a tool of personalized medicine. METHODS:Patients undergoing iChT and HSCT with baseline and post-treatment FDG PET-CTs from January 2008 to July 2015 were included. The following baseline and post-treatment parameters were obtained: SUVmax, SUVmean, SUVpeak, MTVsum, TLGsum, rPET (lesion SUVmax/liver SUVmax) and qPET (lesion SUVpeak/liver SUVmean). Baseline-to-post-treatment changes (Δ) were also calculated. Metabolic and clinical laboratory progression or response at follow-up were noted; time-to-metabolic-progression (TMP) was defined as the interval from post-treatment scan to eventual progression at follow-up FDG PET-CTs. Possible association between each functional parameter and metabolic/clinical-laboratory progression or response was determined. Kaplan-Meier curves allowed to depict the TMP trend according to FDG PET-CT parameters. RESULTS: Twenty-eight patients were included. Significantly higher ΔrPET and ΔqPET values were observed in ten patients with "metabolic response", with respect to 18 patients having "metabolic progression" (median 0.62 [IQR 0.32 - 1.34] vs median 0.00 [IQR -0.25 - 0.49] for ΔrPET; P = 0.045; median 0.51 [IQR 0.32 - 1.13] vs median 0.00 [IQR -0.31 - 0.67] for ΔqPET; P = 0.035). Neither normalized nor non normalized parameters differed significantly between the 20 patients with "clinical-laboratory response" and the eight patients with "clinical-laboratory progression". ΔrPET value lower than 0.38 and ΔqPET value lower than 0.27 predicted a significantly shorter TMP (P = 0.003 and P = 0.005, respectively). CONCLUSIONS: Normalized semi-quantitative parameters are effective in predicting persistent response to treatment and shorter TMP in patients with MM undergoing iChT and HSCT.
Authors: P Moreau; J San Miguel; P Sonneveld; M V Mateos; E Zamagni; H Avet-Loiseau; R Hajek; M A Dimopoulos; H Ludwig; H Einsele; S Zweegman; T Facon; M Cavo; E Terpos; H Goldschmidt; M Attal; C Buske Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976
Authors: Jorge J Castillo; Artur Jurczyszyn; Lucie Brozova; Edvan Crusoe; Jacek Czepiel; Julio Davila; Angela Dispenzieri; Marion Eveillard; Mark A Fiala; Irene M Ghobrial; Alessandro Gozzetti; Joshua N Gustine; Roman Hajek; Vania Hungria; Jiri Jarkovsky; David Jayabalan; Jacob P Laubach; Barbara Lewicka; Vladimir Maisnar; Elisabet E Manasanch; Philippe Moreau; Elizabeth A Morgan; Hareth Nahi; Ruben Niesvizky; Claudia Paba-Prada; Tomas Pika; Ludek Pour; John L Reagan; Paul G Richardson; Jatin Shah; Ivan Spicka; Ravi Vij; Anna Waszczuk-Gajda; Morie A Gertz Journal: Am J Hematol Date: 2017-05-26 Impact factor: 10.047
Authors: Rosa Fonti; Michele Larobina; Silvana Del Vecchio; Serena De Luca; Rossella Fabbricini; Lucio Catalano; Fabrizio Pane; Marco Salvatore; Leonardo Pace Journal: J Nucl Med Date: 2012-10-15 Impact factor: 10.057
Authors: Nicolas Aide; Charline Lasnon; Patrick Veit-Haibach; Terez Sera; Bernhard Sattler; Ronald Boellaard Journal: Eur J Nucl Med Mol Imaging Date: 2017-06-16 Impact factor: 9.236
Authors: Debra Howell; Alexandra Smith; Simon Appleton; Timothy Bagguley; Una Macleod; Gordon Cook; Russell Patmore; Eve Roman Journal: Br J Haematol Date: 2017-02-01 Impact factor: 6.998